KR20160107679A - Development of health functional food for diet from Dendropanax morbifera LEV. - Google Patents
Development of health functional food for diet from Dendropanax morbifera LEV. Download PDFInfo
- Publication number
- KR20160107679A KR20160107679A KR1020150030734A KR20150030734A KR20160107679A KR 20160107679 A KR20160107679 A KR 20160107679A KR 1020150030734 A KR1020150030734 A KR 1020150030734A KR 20150030734 A KR20150030734 A KR 20150030734A KR 20160107679 A KR20160107679 A KR 20160107679A
- Authority
- KR
- South Korea
- Prior art keywords
- obesity
- extract
- development
- dendropanax morbifera
- diet
- Prior art date
Links
- 235000005911 diet Nutrition 0.000 title claims description 4
- 230000037213 diet Effects 0.000 title claims description 3
- 241000392544 Dendropanax morbifer Species 0.000 title abstract description 5
- 235000013376 functional food Nutrition 0.000 title description 4
- 230000036541 health Effects 0.000 title description 3
- 208000008589 Obesity Diseases 0.000 claims abstract description 28
- 235000020824 obesity Nutrition 0.000 claims abstract description 28
- 239000000284 extract Substances 0.000 claims abstract description 16
- 239000000203 mixture Substances 0.000 claims description 13
- 239000004480 active ingredient Substances 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 11
- 230000003579 anti-obesity Effects 0.000 abstract description 2
- 235000012041 food component Nutrition 0.000 abstract 1
- 239000005417 food ingredient Substances 0.000 abstract 1
- 235000013402 health food Nutrition 0.000 abstract 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 6
- 210000001789 adipocyte Anatomy 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 239000000469 ethanolic extract Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 3
- 229940093499 ethyl acetate Drugs 0.000 description 3
- 235000019439 ethyl acetate Nutrition 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000000972 4,5-dimethylthiazol-2-yl group Chemical group [H]C([H])([H])C1=C(N=C(*)S1)C([H])([H])[H] 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 241001600434 Plectroglyphidodon lacrymatus Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- RSWGJHLUYNHPMX-ONCXSQPRSA-N abietic acid Chemical compound C([C@@H]12)CC(C(C)C)=CC1=CC[C@@H]1[C@]2(C)CCC[C@@]1(C)C(O)=O RSWGJHLUYNHPMX-ONCXSQPRSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 239000012223 aqueous fraction Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 239000002034 butanolic fraction Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000002036 chloroform fraction Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000002038 ethyl acetate fraction Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 210000002468 fat body Anatomy 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 239000002044 hexane fraction Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Botany (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
The present invention relates to a method for producing yellow crunch and a composition for improving obesity comprising the yellow crunch extract prepared by the method as described above. Yellow crunch is a yellow resin liquid which is discharged by scarring the bark of yellowtail, It is a high-quality paint with effect, it is warm, it has efficacy on gourmetsu, sulfur and hemoglobin, and has ability to remove active oxygen. It accelerates the growth of immune cells and strengthens early immune system and defense system against causes causing various diseases. But there is no report on the anti-obesity effect and there is no related product. Therefore, it is aimed to develop the functional product by carrying out the related research
Obesity is regarded as obesity when body weight is over 20% above the maximum value of healthy body weight, which is calculated according to height with excess body fat accumulation
Over the world, obesity is increasing, overweight and obesity are leading to various complications and emerging as a social problem. So far, many products have been developed that are highly effective in relation to obesity. Many products have been developed to inhibit obesity through various routes such as promoting fat metabolism in obese patients or suppressing food intake, but most of them are made of chemical synthetic substances and cause severe side effects in spite of excellent efficacy.
In addition, as the economic growth and the income level are improved, the dietary culture is rapidly changing, and the obesity is rapidly increasing. This leads to diabetes and hypertension easily, and the incidence of the degenerative diseases such as heart disease, stroke and cancer also increases. Since obesity causes not only medical expenses but also various diseases, it leads to social and economic losses. Therefore, it can reduce social cost by reducing annual disease cost caused by obesity.
In order to meet such a demand, the present invention aims to provide a composition for improving obesity containing an effective amount of a plant extract which is less likely to cause side effects.
In order to achieve the above object, the present invention hwangchil tree (Dendropanax morbifera ) as an active ingredient.
Accordingly, the present invention has been made to investigate the effect of suppressing obesity, which is a natural food material that can suppress obesity without side effects, using obesity.
About 30% of the population in Korea wants to lose weight, and interest in diet products and obesity treatment is increasing rapidly. However, more than half of the obesity drugs sold on the market are appetite suppressants, and side effects such as myocardial infarction and stroke have been reported, and the health authorities are trying to refrain from prescription or preparation. The present inventors sought to find a solution in natural food materials that can suppress obesity without side effects, and to develop functional foods for the prevention and treatment of obesity.
In addition, the present invention provides a method of inhibiting adipocyte differentiation by using Huangchil extract, having excellent cytostability due to no cytotoxicity, identifying the mechanism of inhibiting adipocyte differentiation, gradually inducing lipid metabolism and differentiation of adipocyte precursor cells, And a method for producing the derivative.
It is another object of the present invention to provide a pharmaceutical composition for improving obesity and a food composition comprising the Huangchil extract derivative prepared by the above method as an active ingredient.
In order to attain the above object, there is provided an obesity improving composition comprising as an active ingredient the manufactured Huangchir extract.
The present invention also provides a pharmaceutical composition for improving obesity and a food composition comprising the Huangchu extract derivative prepared by the above method as an active ingredient.
As described above, the present invention can provide a composition for improving obesity. The composition for improving obesity and the like of the present invention can be commercialized as a functional food, medicine and the like.
Cell activity
Hereinafter, the present invention will be described in detail.
EXAMPLES Preparation of extracts and fractions
- In 2014, leaves, branches and roots of Hwangchujang were collected from the southern coast of Jeonnam, Jangheung, and then lyophilized to remove moisture. Each part of the water-removed Hwangchu-myeon was crushed and homogenized. Then, 100 g of the extracting solvent was added to 5 g of the powder of the Hwachung-gil leaf, and the mixture was stirred at 55 캜 for 24 hours. The extraction solvent used for the preparation of the extract was an aqueous ethanol solution prepared by mixing distilled water and ethanol to make distilled water, 25%, 50%, and 75% of 100% ethanol and ethanol. After 24 hours of extraction, the mixture was filtered using a filter paper (Wattman 41). The filtrate was concentrated under reduced pressure and freeze-dried at -40 ° C for 48 hours using a freeze dryer.
The extract was prepared by dissolving 0.435 g of water extract (hereinafter referred to as DMO), 0.25 g of 25% ethanol extract (hereinafter referred to as DM25E), 50% ethanol extract (hereinafter referred to as DM50E) 0.71 0.775 g of a 75% ethanol extract (hereinafter referred to as DM75E) and 0.855 g of a 100% ethanol extract (hereinafter referred to as DM100E) were respectively obtained.
<Example 1> Preparation of extract of Hwangchu
First, distilled water and hexane were added at a ratio of 1: 1 to 200 g of the water extract of DMG (DMO), and then the water layer and the hexane layer were separated to obtain a hexane layer. The hexane layer was separated, and water and chloroform were further added thereto at a ratio of 1: 1. The chloroform layer was fractionated as described above. The chloroform layer was separated, and water and ethylacetate were added thereto at a ratio of 1: 1. The ethyl acetate layer was fractionated as described above. The butanol layer was finally fractionated by adding water and buthanol 1: 1 again to the water layer from which the ethyl acetate layer was separated, and obtaining a butanol layer as described above. 0.72 g, 1.9 g, 3.4 g, 8.6 g and 116.62 g of a hexane fraction, a chloroform fraction, an ethyl acetate fraction, a butanol fraction and a water fraction, respectively, of the hot water extract of Pochuchoi leaf were obtained by evaporating and concentrating the respective fractions obtained above .
≪ Experimental Example >
<Experimental Example 1> Cytotoxicity confirmation
Cellular toxicity was analyzed by MTT (3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyl tetraxolium bromide) (Sigma). This method measures the conversion of MTT to formazan, in which 3T3-L1 cells are seeded in 96-well plates and each of the yellowish concentrate is treated for 24 hours by concentration. 100 μl of MTT solution per well was added and reacted for 4 hours at 37 ° C in a 5% CO2 incubator. Cell viability was then expressed as a percentage of the control by measuring the absorbance at 540 nm using a microplate reader.
Experimental Example 2: 3T3-L1 adipocyte differentiation and oil-red O staining
3T3-L cells were cultured in 24-well plates and differentiation was induced for 2 days by precisely treating the cells with hormone mixtures (1uM dexamethason, 5 ug / ml insulin, and ug / ml IBMX) before differentiation. After 2 days, the cells were cultured for 8 days in DMEM medium containing 5 ug / ml insulin and 10% fetal bovine serum. On day 8, the cells were stained with Oil-Red O dye. Small fat bodies of adipocytes are stained with red.
none
Claims (3)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150030734A KR20160107679A (en) | 2015-03-05 | 2015-03-05 | Development of health functional food for diet from Dendropanax morbifera LEV. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150030734A KR20160107679A (en) | 2015-03-05 | 2015-03-05 | Development of health functional food for diet from Dendropanax morbifera LEV. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20160107679A true KR20160107679A (en) | 2016-09-19 |
Family
ID=57103135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020150030734A KR20160107679A (en) | 2015-03-05 | 2015-03-05 | Development of health functional food for diet from Dendropanax morbifera LEV. |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20160107679A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023075489A1 (en) * | 2021-10-28 | 2023-05-04 | 국제뇌교육종합대학원대학교 산학협력단 | Pharmaceutical composition for preventing or treating metabolic syndrome-related diseases, comprising, as active ingredient, dendropanax trifidus sap extract or compound derived therefrom |
-
2015
- 2015-03-05 KR KR1020150030734A patent/KR20160107679A/en not_active Application Discontinuation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023075489A1 (en) * | 2021-10-28 | 2023-05-04 | 국제뇌교육종합대학원대학교 산학협력단 | Pharmaceutical composition for preventing or treating metabolic syndrome-related diseases, comprising, as active ingredient, dendropanax trifidus sap extract or compound derived therefrom |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20180003073A (en) | Composition for treating or preventing obesity containing young barley leaves extract | |
| KR102315959B1 (en) | A composition for reinforcing immune function comprising the extract of oat sprout | |
| KR101692032B1 (en) | Anti-cancer composition containing erythronium japonicum extract | |
| KR102334546B1 (en) | Composition for anti-inflammatory comprising male pupa extract | |
| KR20160107679A (en) | Development of health functional food for diet from Dendropanax morbifera LEV. | |
| US11752187B2 (en) | Anti-obesity composition including Geumhwagyu extract as active ingredient | |
| KR101851639B1 (en) | Composition for anti-obesity comprising Chaenomelis Fructus extract or its fraction as effective component | |
| KR20150077794A (en) | Anti-obesity composition comprising herbal extracts as an active ingredient | |
| KR20140041187A (en) | Anti-cancer composition containing erythronium japonicum extract | |
| KR101760163B1 (en) | Composition for anti-obesity comprising extract of Sargassum serratifolium as an effective component | |
| KR20230014156A (en) | Composition for Anti-Obesity Comprising Catechin, and Complex Extracts of Rosa davurica Pall as Active Ingredient | |
| KR20180098883A (en) | Composition for anti-obesity or reducing body-fat having extract of peanut sprouts as active component | |
| KR101257329B1 (en) | Composition for treating or preventing obesity containing stichpus japonicus extract | |
| KR101001159B1 (en) | Composition for preventing or improving the diabete containing eriobotrya japonica extract | |
| KR20100116919A (en) | Compositions comprising extract from codonopsis lanceolata for preventing or treating obesity, hyperlipidemia or fatty liver | |
| KR101910099B1 (en) | Compositions for improving lipid metabolism or anti-obesity as an active ingredient extracted from an immature persimmon by pressurized hydrothermal method | |
| KR101724587B1 (en) | Composition for treating, improving or preventing liver injury and liver dysfunction | |
| JP2009249331A (en) | Plant-originated agent for preventing or ameliorating hyperlipemia | |
| KR20140145666A (en) | Composition comprising natural complex of fucoxanthin, salix babylonica and low molecular weight alginate for preventing or treating of obesity | |
| KR20200072952A (en) | A composition for prevention and treatment of osteoporosis comprising extracts of Saechalssalbori | |
| KR20190061786A (en) | A composition for the improvement, prevention or treatment of obesity and hyperlipidemia | |
| KR101203111B1 (en) | Compositions Comprising Extract from Codonopsis lanceolata for Improving Obesity, Hyperlipidemia or Fatty Liver, and Functional Food Containing The Same | |
| KR20130082249A (en) | Composition for preventing or improving the metabolic syndrome containing parthenocissus tricuspidata extract | |
| KR102025572B1 (en) | Composition for preventing, ameliorating or treating metabolic diseases comprising mixture of Diospyros lotus leaf and grape fruit stem extract as effective component | |
| KR102187385B1 (en) | Composition for enhancing immunological activity comprising herbal extracts and method for producing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application | ||
| E601 | Decision to refuse application |